Pegteograstim in Children With Solid Tumors

Inclusion Criteria: * Patients with solid tumor who undergo chemotherapy with carboplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen Exclusion Criteria: * Patients with organ dysfunction (creatinine \> 2mg/dL, ejection fraction \<40% or severe arrhythmia/conduction disorder, other severe organ dysfunction) * Hypersensitivity to pegteograstim, protein originated from E-coli, pegfilgrastim, filgrastim or latex. * Patients with bleeding tendency to whom subcutaneous injection should be avoided. * Active infection or infectious fever during the screening period. * Genetic problem to fructose tolerance. * Patients who participated in other clinical trial within 4 weeks before enrollment. * Pregnant and nursing women